Arbekacin 약물 사용 평가
Drug Use Evaluation of Arbekacin
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Arbekacin is a semisynthetic aminoglycoside antibiotic. It is used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA which consequently, leaves the bacterium unable to synthesize proteins vital to its growth. Pharmacokinetic advantages such as concentration-dependant bactericidal activity and prolonged post-antibiotic effect are more appropriate than vancomycin. However, there are only a few reports of clinical data of this antibiotic use against MRSA infections. Therefore, this study was performed to evaluate the use of arbekacin and to evaluate the effects of arbekacin in the treatment of MRSA infections. We retrospectively analyzed medical records of patients who received arbekacin in Chonbuk National University Hospital from January 2009 to May 2010. As result, 103 patients were studied, and the justification of use showed high rate of appropriate use(92.2%). Most of the critical(process) indicators also showed high rate of appropriate use(89.3%~100%). The incidence of complications in arbekacin use was nephrotoxicity 7.8% and hepatotoxicity 7.8%. In outcomes measure, the total therapeutic response rate showed 67%. This study showed that arbekacin was used appropriately. And arbekacin was not inferior drug to vancomycin(vancomycin therapeutic response rates: 66.9~88%) and it could be a good alternative drug for vancomycin in MRSA treatment.
Abstract
Arbekacin is a semisynthetic aminoglycoside antibiotic. It is used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA which consequently, leaves the bacterium unable to synthesize proteins vital to its growth. Pharmacokinetic advantages such as concentration-dependant bactericidal activity and prolonged post-antibiotic effect are more appropriate than vancomycin. However, there are only a few reports of clinical data of this antibiotic use against MRSA infections. Therefore, this study was performed to evaluate the use of arbekacin and to evaluate the effects of arbekacin in the treatment of MRSA infections. We retrospectively analyzed medical records of patients who received arbekacin in Chonbuk National University Hospital from January 2009 to May 2010. As result, 103 patients were studied, and the justification of use showed high rate of appropriate use(92.2%). Most of the critical(process) indicators also showed high rate of appropriate use(89.3%~100%). The incidence of complications in arbekacin use was nephrotoxicity 7.8% and hepatotoxicity 7.8%. In outcomes measure, the total therapeutic response rate showed 67%. This study showed that arbekacin was used appropriately. And arbekacin was not inferior drug to vancomycin(vancomycin therapeutic response rates: 66.9~88%) and it could be a good alternative drug for vancomycin in MRSA treatment.
참고문헌 (17)
- "Habekacin product documentation", Choongwae Pharmaceutical, ~
- Kobayashi Y, "Arbekacin", Int J Antimicrob Agents, 5, pp.227~230 (1995)
- Watanabe T, "Comparative studies of the bactericidal, morphological and postantibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus", J Antimicrob Chemother, 39, pp.471~476 (1997)
- 위성헌, "Staphylococcus aureus와 coagulase-negative staphylococcus species 에대한 arbekacin의 시험관내 항균력", 감염, 33, pp.254~260 (2001)
- Cunha B.A, "Methicillin-resistant Staphylococcus aureus ; clinical manifestations and antimicrobial therapy", Clin Microbiol Infect, 11, pp.33~42 (2005)
- 이혁민, "2004년도 국내 12개 병원에서 분리된 주요 세균의 항균제 내성율", Annals of Clinical Microbiology, 8(1), pp.66~73 (2005), 대한임상미생물학회
- 오향순, "Multicenter surveillance study for nosocomial infections in major hospitals in Korea", American Journal of Infection Control, 28(6), pp.454~458 (2000), Mosby Inc.
- 류지소, "그람양성균 감염증에 대한 teicoplanin의 효능", 감염, 24, pp.183~190 (1992)
- 배인규, "국내감염증의 항생제치료", 대한화학요법학회지, 19, pp.253~262 (2001)
- 우준희, "우리나라에서 항균제 내성", 대한내과학회지, 57, pp.578~586 (1999)
- Deguchi K, "Antimicrobial activites of arbekacin against methicillin-resistant Staphyloco ccus aureus", Jpn J Antibiot, 50(1), pp.1~11 (1997)
- Yamazaki T, "Epidemiological study of arbekacin-resistant, methicillin resistant Staphylococcus aureus in Saitama Medical School Hospital", Kansenshogaku Zasshi, 78(4), pp.305~311 (2004)
- 김홍빈, "3차 병원에서 분리된 황색포도구균의 아미노글리코사이드 내성빈도", Infection and Chemotherapy, 34(1), pp.39~46 (2002), 대한감염학회
- 이선민, "국내에서 최근 분리된 황색포도알균에 대한 Arbekacin의 항균력", Annals of Clinical Microbiology, 9(1), pp.13~17 (2006), 대한임상미생물학회
- J. Neal Sharpe, "Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lowerextremity skin and soft-tissue infections caused by methicillin-resistant Staphy lococcus aureus", The American Journal of Surgery, 189, pp.425~428 (2005)
- John Weigelt, "Linezolid versusvancomycin in treatment of complicated skin and soft tissue infections", Antimicrobial agents and chemotherapy, pp.2260~2266 (2005)
- Kamal M.F. Itani, "Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillinresistant Staphylococcus aureus", The American Journal of Surgery, 199, pp.804~816 (2010)